AR023715A1 - Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel - Google Patents

Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel

Info

Publication number
AR023715A1
AR023715A1 ARP990106107A ARP990106107A AR023715A1 AR 023715 A1 AR023715 A1 AR 023715A1 AR P990106107 A ARP990106107 A AR P990106107A AR P990106107 A ARP990106107 A AR P990106107A AR 023715 A1 AR023715 A1 AR 023715A1
Authority
AR
Argentina
Prior art keywords
skin
subject
pharmaceutical composition
manufacture
needs
Prior art date
Application number
ARP990106107A
Other languages
English (en)
Original Assignee
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22333250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR023715(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kentucky Res Found filed Critical Univ Kentucky Res Found
Publication of AR023715A1 publication Critical patent/AR023715A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Se describe una composicion farmacéutica para un sujeto que necesita una elevacion del contenido de NAD intracelular, que comprende un agente pro-NAD y unvehículo farmacéuticamente aceptable, donde dicho agente pro-NAD está en una concentracion suficiente para elevar el NAD intracelular en dicho sujeto y uso deuna composicion farmacéutica en una cantidad efectiva para tratar o retardar el deterioro de la piel que es para la manufactura de un medicamento para tratar oretardar el deterioro de la piel.
ARP990106107A 1998-12-01 1999-12-01 Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel AR023715A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11048298P 1998-12-01 1998-12-01

Publications (1)

Publication Number Publication Date
AR023715A1 true AR023715A1 (es) 2002-09-04

Family

ID=22333250

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106107A AR023715A1 (es) 1998-12-01 1999-12-01 Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel

Country Status (15)

Country Link
US (4) US6337065B1 (es)
EP (1) EP1143954B1 (es)
AR (1) AR023715A1 (es)
AT (1) ATE273008T1 (es)
AU (1) AU762770B2 (es)
CA (1) CA2352964C (es)
DE (1) DE69919403T2 (es)
DK (1) DK1143954T3 (es)
ES (1) ES2228146T3 (es)
HK (1) HK1041436B (es)
IL (2) IL143112A0 (es)
NZ (1) NZ511708A (es)
PT (1) PT1143954E (es)
TW (1) TWI257303B (es)
WO (1) WO2000032179A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1143954B1 (en) * 1998-12-01 2004-08-11 University of Kentucky Research Foundation Use of nicotinic acid derivatives for the treatment of dna damage in skin cells
US6531500B2 (en) 1999-07-23 2003-03-11 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
US6864274B2 (en) 1999-07-23 2005-03-08 Alwyn Company, Inc. Allantoin-containing skin cream
US20020054895A1 (en) 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
US6896897B2 (en) 1999-07-23 2005-05-24 Alwyn Company, Inc. Flexible applicator for applying oil-in-water emulsion with improved stability
US6673826B2 (en) 1999-07-23 2004-01-06 Alwyn Company, Inc. Methods for treatment of inflammatory diseases
JP4041674B2 (ja) * 2000-04-14 2008-01-30 ナイアダイン コーポレーション 細胞への酸素送達の強化に役立つ方法および組成物
EP1274429B1 (en) * 2000-04-14 2008-05-14 Niadyne Corporation Topical formulations for the transdermal delivery of niacin prodrugs and methods of treating hyperlipidemia
US20020182585A1 (en) * 2001-01-10 2002-12-05 George Kindness Combination and method using EDTA, cystine, zinc and selenium for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
CA2437844C (en) * 2001-03-08 2007-05-15 Elaine Jacobson Method for increasing leptin levels using nicotinic acid compounds
ITMI20011019A1 (it) * 2001-05-17 2002-11-17 Carlo Ghisalberti Sostanze furiliche per uso topico
AU2002950744A0 (en) * 2002-08-13 2002-09-12 Medihoney Pty Ltd Composition
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
NZ540506A (en) * 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
JP5074661B2 (ja) * 2002-12-26 2012-11-14 味の素株式会社 肝癌発生・進展抑制剤
US20040161435A1 (en) * 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
WO2004100990A1 (ja) 2003-05-19 2004-11-25 Genecare Research Institute Co., Ltd. 癌細胞に対するアポトーシス誘導剤
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
US7615641B2 (en) * 2004-07-20 2009-11-10 Sino Pharmaceuticals Corporation Long chain aliphatic alcohol derivatives and methods of making and using same
DK1898867T3 (da) 2005-06-24 2017-11-20 Arizona Board Of Regents Acting On Behalf Of The Univ Of Arizona Fremgangsmåde til behandling af hårvækstforstyrrelser, såsom alopeci hos kvinder og sammensætninger, der er anvendelige dertil
WO2007136744A1 (en) * 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
WO2008025755A1 (de) * 2006-09-01 2008-03-06 Basf Se Verwendung von n-haltigen heterozyklen in dermokosmetika
JP5448839B2 (ja) * 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
CN101742916B (zh) * 2007-02-28 2015-08-19 肯塔基大学研究基金会 减轻视黄酸治疗副作用和/或改进疗效而不干扰疗效的方法
US8815936B2 (en) * 2008-03-03 2014-08-26 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
EP2168574A1 (en) 2008-09-25 2010-03-31 Noureddine Frid Compound for local deletion of tumors
US8173446B2 (en) 2009-12-21 2012-05-08 General Electric Company Method of producing an integrated micromagnet sensor assembly
US20140135372A1 (en) 2010-02-02 2014-05-15 Elliott Farber Compositions and methods of treatment of inflammatory skin conditions using allantoin
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
WO2016178207A1 (en) * 2015-05-04 2016-11-10 Ramot At Tel-Aviv University Ltd. Methods and kits for fragmenting dna
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
EP3873415A1 (en) 2018-11-02 2021-09-08 Unilever Global Ip Limited Bioenergetic nicotinic acid glycerol esters, compositions and methods of using same
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3185679A (en) 1965-05-25 Azepine derivatives
US3276960A (en) 1961-08-21 1966-10-04 Kendall & Co Analgesic methods and compositions
US4246285A (en) 1975-10-20 1981-01-20 The Procter & Gamble Company Skin conditioning compositions containing guanidine inorganic salts
HU184626B (en) 1979-06-01 1984-09-28 Ferrokemia Ipari Congesting cosmetics first of all hair-restorers
EP0057797B1 (en) 1981-02-03 1986-06-25 Imperial Chemical Industries Plc Process for the extraction of metal values and novel metal extractants
US4607101A (en) 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
US5635497A (en) 1982-06-23 1997-06-03 Yamanouchi Europe B.V. Topical application compositions
US4459153A (en) 1982-09-20 1984-07-10 The United States Of America As Represented By The United States Department Of Energy Pyrochemical process for extracting plutonium from an electrolyte salt
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
EP0158090B1 (de) 1984-03-07 1990-08-29 Roshdy Dr. Ismail Mittel zur Behandlung und zum Schutz der Haut
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
DE3570598D1 (en) 1984-11-15 1989-07-06 Nitto Denko Corp Composition for percutaneous administration
US5053396A (en) * 1985-08-27 1991-10-01 Blass David H Therapeutic composition
DE3532562A1 (de) 1985-09-12 1987-03-12 Dolorgiet Gmbh & Co Kg Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben
LU86574A1 (fr) 1986-09-08 1988-04-05 Oreal Composition pour induire et stimuler la croissance des cheveux et freiner leur chute,a base d'esters nicotiniques et de derives de pyrimidine
GB2216003B (en) 1988-02-18 1992-06-10 Toyama Chemical Co Ltd Hair restorer
US4981681A (en) 1988-08-26 1991-01-01 Vittorio Tosti Lotion mixture and method of treating psoriasis
US5077313A (en) 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
US5133958A (en) 1989-04-20 1992-07-28 Erwin Stuckler Agent for nail, skin and hair care
US5129360A (en) 1990-01-24 1992-07-14 The United States Of America As Represented By The Secretary Of The Air Force Actively cooled effusion cell for chemical vapor deposition
GB9006785D0 (en) 1990-03-27 1990-05-23 Leung Lit Hung Composition and methods for treatment of acne vulgaris and retardation of ageing
US5114957A (en) 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5043162A (en) 1990-09-05 1991-08-27 Trager Seymour F Hair growth promoter
FR2668366B1 (fr) 1990-10-30 1993-01-29 Oreal Utilisation cosmetique d'une composition ayant une activite antierythemale et composition correspondante.
GB9114346D0 (en) 1991-07-03 1991-08-21 Dow Corning Sa A method of accelerating drug permeation
US5358969A (en) 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US5240945A (en) 1992-02-18 1993-08-31 Warshaw Thelma G Method and compositions for treating acne
US5318960A (en) 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
US5449688A (en) 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
US6231852B1 (en) * 1993-11-18 2001-05-15 The Regents Of The University Of California Method for reducing BCL-2 expressing cells resistance to death
FR2715565B1 (fr) 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
CA2191837C (en) * 1994-06-02 2002-10-15 Dan Riga Anti-stress, anti-impairment and anti-aging drug and process for manufacturing thereof
US5612382A (en) 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5496827A (en) 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
DE4433130C2 (de) 1994-09-16 1997-02-06 Deutsches Krebsforsch Poly(ADP-Ribose)-Polymerase überexprimierende tierische Zellinien und Verfahren zur Identifizierung von DNA-schädigenden Substanzen
DE69533714T2 (de) 1994-12-20 2005-03-24 Unilever N.V. Lactat-dehydrogenase Inhibitoren in kosmetischen Mitteln
US5690944A (en) 1994-12-20 1997-11-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing lactate dehydrogenase inhibitors
JPH11501934A (ja) * 1995-03-14 1999-02-16 シャスカン，エドワード・ジー ニコチニルアラニンと、グリシン抱合の阻害薬又はビタミンｂ６とを含む組成物
NZ306510A (en) 1995-05-01 1999-05-28 Scotia Holdings Plc Niacin derivatives which include a fatty acid or fatty acid alcohol residue and their use in medicaments and skin care compositions
JPH08301760A (ja) 1995-05-10 1996-11-19 Shiseido Co Ltd 皮膚外用剤
US5571794A (en) 1995-06-22 1996-11-05 Frome; Bruce M. Non-invasive novel method fo cosmetic lip augmentation
JP3542665B2 (ja) 1995-07-07 2004-07-14 株式会社資生堂 抗老化皮膚外用剤、コラーゲン架橋阻害皮膚外用剤及び抗紫外線皮膚外用剤
ES2238695T3 (es) * 1995-08-14 2005-09-01 Optigenex, Inc. Composiciones de carotenoide-nicotinamida-zinc y metodos de tratamiento usando las mismas.
US5939082A (en) * 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
CZ235798A3 (cs) * 1996-01-24 1999-03-17 Aliatros Medical, A. S. Prostředek pro léčení rakoviny a způsob jeho výroby
US5736529A (en) * 1996-03-22 1998-04-07 Neurocal International Inc. Use of NAD-related compounds in the treatment of neural trauma to inhibit neurodegeneration
AUPN892496A0 (en) * 1996-03-25 1996-04-18 Technical Consultancy Services Pty Limited Acne treatment
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
JP2002506801A (ja) * 1998-03-16 2002-03-05 ザ、プロクター、エンド、ギャンブル、カンパニー 哺乳類の皮膚のセルライトを軽減する方法
US6277613B1 (en) 1998-06-10 2001-08-21 The Rockefeller University TRF1 binding protein, methods of use thereof
US6149924A (en) * 1998-07-20 2000-11-21 Biomed Research & Technologies, Inc. Composition for enhancing lipid production, barrier function, hydrogen peroxide neutralization, and moisturization of the skin
US5976513A (en) 1998-10-16 1999-11-02 The Procter & Gamble Company UV protection compositions
EP1143954B1 (en) * 1998-12-01 2004-08-11 University of Kentucky Research Foundation Use of nicotinic acid derivatives for the treatment of dna damage in skin cells

Also Published As

Publication number Publication date
HK1041436A1 (en) 2002-07-12
CA2352964A1 (en) 2000-06-08
HK1041436B (zh) 2005-03-11
TWI257303B (en) 2006-07-01
DE69919403T2 (de) 2005-09-08
AU1929200A (en) 2000-06-19
US20040147491A1 (en) 2004-07-29
CA2352964C (en) 2006-10-17
US6337065B1 (en) 2002-01-08
ES2228146T3 (es) 2005-04-01
NZ511708A (en) 2003-12-19
EP1143954B1 (en) 2004-08-11
DK1143954T3 (da) 2004-12-20
DE69919403D1 (de) 2004-09-16
IL143112A0 (en) 2002-04-21
US6403619B1 (en) 2002-06-11
WO2000032179A2 (en) 2000-06-08
US6552050B2 (en) 2003-04-22
WO2000032179A3 (en) 2001-12-13
PT1143954E (pt) 2004-12-31
AU762770B2 (en) 2003-07-03
EP1143954A2 (en) 2001-10-17
IL143112A (en) 2006-10-31
ATE273008T1 (de) 2004-08-15
US20010033848A1 (en) 2001-10-25
US7425319B2 (en) 2008-09-16

Similar Documents

Publication Publication Date Title
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
KR980000447A (ko) 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
AR002944A1 (es) Uso de una composicion de gel acuosa que contiene una o mas drogas que son eficaces para tratar hemorroides para la preparacion de un medicamento y dicha composicion de gel acuosa
BR0115847A (pt) Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
ATE378058T1 (de) Cannabis extrakten pharmazeutische zusammensetzung
WO2002043652A3 (en) Anti-proliferative drugs
AR028959A1 (es) Uso de rapamicina para la manufactura de un medicamento para tratar enfermedades cardiovasculares
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
ES2174337T3 (es) Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
SE0003092D0 (sv) New Use
DE602004014964D1 (de) Pharmazeutische zusammensetzung mit einem kationischen hilfsmittel

Legal Events

Date Code Title Description
FG Grant, registration